ACCESS Newswire

MorphoSys AG

Share
Invitation to MorphoSys' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021

PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT).

MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and provide a further outlook for 2021.

The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call:

  • Jean-Paul Kress, M.D., Chief Executive Officer
  • Sung Lee, Chief Financial Officer
  • Roland Wandeler, Ph.D., Chief Operating Officer
  • Malte Peters, M.D., Chief Research & Development Officer

A live webcast and slides will be made available at the Media and Investors section under Conferences on MorphoSys' website, www.morphosys.com .

Dial-in number for the conference call (2:00pm CEST, 8:00am EDT):

Germany: +49 69 201 744 220
For UK residents: +44 203 009 2470
For US residents: +1 877 423 0830
(all numbers reachable from any geography)
Participant PIN: 72989449#

Please dial in 10 minutes before the beginning of the conference.

A replay of the conference will also be available at the corporate website following the live event.

About MorphoSys
MorphoSys (FSE:MOR)(NASDAQ:MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya (R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (R) (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.com or www.morphosys-us.com .

Monjuvi (R) is a registered trademark of MorphoSys AG.
Tremfya (R) is a registered trademark of Janssen Biotech, Inc.

Forward Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

For more information, please contact:

Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 899 27 26 079
thomas.biegi@morphosys.com

Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com

Jeanette Bressi
Director, US Communications
Tel: +1 617 404 7816
jeanette.bressi@morphosys.com

Myles Clouston
Senior Director
Tel: +1 857 772 0240
myles.clouston@morphosys.com

SOURCE: MorphoSys AG



View source version on accesswire.com:
https://www.accesswire.com/656539/Invitation-to-MorphoSys-Second-Quarter-and-First-Half-2021-Results-Conference-Call-on-July-29-2021

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Gun, Cocaine, and a High-Speed Chase: Luton Crime Haul Sparks Fresh Questions and Public Appeal11.7.2025 13:45:00 CEST | Press release

Officers discovered an estimated 25 kilograms of suspected Class A drugs, tightly packed and hidden in secret compartments. Alongside the drugs, they recovered a Beretta 92FS 9mm semi-automatic handgun, loaded with 38 rounds of ammunition. LUTON, GB / ACCESS Newswire / July 11, 2025 / A dramatic police pursuit through Luton on the night of June 29 resulted in the seizure of a loaded firearm and an estimated £600,000 worth of suspected cocaine. Nearly a week later, crucial questions remain unanswered, and police are still searching for individuals who fled the scene. The incident, which unfolded between 11:30 PM and 1:00 AM, began in Marsh Farm when Bedfordshire Police officers attempted to stop a vehicle as part of a proactive investigation into organised criminal activity. The driver failed to stop, sparking a high-speed chase that stretched through Dallow, Farley Hill, and eventually ended on Beechwood Road, where the vehicle was forcibly brought to a halt. Inside, officers discovere

The Battery Show Europe Showcases Global Acceleration10.7.2025 10:00:00 CEST | Press release

Europe's flagship event advancing the battery and EV industry from cell design to policy frameworks STUTTGART, GERMANY / ACCESS Newswire / July 10, 2025 / The Battery Show Europe and Electric & Hybrid Vehicle Technology Expo Europe, co-located with Energy Storage Summit Germany (ESG), welcomed over 17,000 industry professionals and more than 1,100 exhibitors to Messe Stuttgart. This combined event represents the only place where the entire advanced battery, electric & hybrid vehicle technology and energy storage supply chain can be accessed under one roof. From breakthrough technologies and policy insights to hands-on demos and global partnerships, the 2025 edition captured the rapid pace of industry evolution and the growing international significance. Keynote sessions across the three-day event featured high-profile speakers from across the battery, automotive and energy sectors, including BMW Group, Verkor, Mercedes-Benz, CATL and Shanghai Putailai New Energy Technology Co., Ltd. Th

Eagle Football Chairman John Textor Congratulates Olympique Lyonnais on Qualification for Ligue 1 and UEFA Europa League9.7.2025 18:55:00 CEST | Press release

PALM BEACH GARDENS, FL / ACCESS Newswire / July 9, 2025 / John Textor, Chairman and CEO of Eagle Football Holdings, today issued the following statement in response to the decision by the French Football Federation (FFF) to uphold Olympique Lyonnais's (OL) appeal, reversing the earlier decision of the DNCG, and confirming OL's participation in Ligue 1 and UEFA Europa League: John Textor, Chairman and majority owner of Eagle Football Holdings, stated: "I would like to congratulate our whole team at Olympique Lyonnais for demonstrating clearly what we have long known, that our great club in Lyon is financially strong and ready to continue its climb up the tables in France and in Europe. We previously cleared through a rigorous sustainability review by UEFA, and now, under the remarkable leadership of our Chair Michele Kang, OL has succeeded on appeal, in cooperation with the DNCG, to confirm our place in Ligue 1 and in Europa League." He continued, "Today's decision is a vital recognitio

Sandline Global Expands International Presence with New London Office9.7.2025 15:15:00 CEST | Press release

LONDON, GB / ACCESS Newswire / July 9, 2025 / Sandline Global, a leading provider of legal technology, eDiscovery, and litigation support services, is proud to announce the opening of its new office in London. This milestone marks a strategic expansion of Sandline's international footprint and reinforces the company's commitment to serving clients across the UK and broader EMEA region.Sandline Global Logo Sandline Global Logo The decision to establish a permanent presence in London was driven by significant and sustained demand for Sandline's services in the region. With a growing number of cross-border matters and increasing interest in Sandline's capabilities-including digital forensics, eDiscovery services, and managed review-the new location will enable the company to deliver tailored, more localized support to clients with complex legal and regulatory needs. "Our expansion into London reflects both the strength of our partnerships in the UK and our long-term vision for internation

Agassi Sports Entertainment Engages IBM to Help Elevate Racquet Sports Experience9.7.2025 14:30:00 CEST | Press release

LAS VEGAS, NV / ACCESS Newswire / July 9, 2025 / Agassi Sports Entertainment Corp. (OTC PINK:AASP), an emerging leader in sports entertainment and innovation, is pleased to announce an exciting collaboration with IBM (NYSE:IBM) which includes the planned use of AI aimed at transforming the digital landscape for various racquet sports worldwide. As two iconic brands with strong connections to racquet sports, and a shared commitment to excellence, Agassi Sports Entertainment has engaged IBM to help create what Agassi Sports Entertainment believes will be an unrivaled digital experience that caters to players and fans alike. This relationship represents a unique fusion of passion, technology, and innovation that Agassi Sports Entertainment expects will not only enhance the way people engage with racquet sports but will also elevate the sport's overall accessibility and enjoyment. Our joint efforts are planned to focus on harnessing cutting-edge technology to deliver personalized experienc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye